Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 26,224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Patient Clear all
Completed Not applicable Interventional

Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

NCT02575027
View directory record Official record
Conditions
Glioblastoma, Recurrent Brain Neoplasm
Interventions
Palliative Radiation Therapy, Questionnaire Administration, Radiation Therapy Treatment Planning and Simulation
Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 22, 2026, 4:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

NCT07751042
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
STX-003, KEYTRUDA®
Biological
Lead sponsor
Strand Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

NCT02412670
View directory record Official record
Conditions
High Grade Upper Tract Urothelial Carcinoma
Interventions
Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine, Carboplatin, Pegfilgrastim, Nephroureterectomy
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
134
States / cities
Birmingham, Alabama • Aurora, Colorado • Colorado Springs, Colorado + 93 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 22, 2026, 4:06 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

NCT02785952
View directory record Official record
Conditions
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1201
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

NCT07049848
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Atezolizumab, Doxorubicin Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

NCT01387555
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, HCC
Interventions
JX-594 recombinant vaccina GM-CSF, Best Supportive Care
Biological · Other
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
La Jolla, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

NCT00854126
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Solid Cancers
Interventions
GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Not applicable Interventional

MRI/MRSI in Risk Assessment of Prostate Cancer Patients

NCT00582543
View directory record Official record
Conditions
Prostate Cancer
Interventions
eMRI/MRSI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors

NCT00016185
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvocidib, docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer

NCT01117935
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
intensity modulated external beam radiation therapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

NCT00135408
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Ipilimumab+ Placebo, Ipilimumab+ Budesonide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

NCT00219817
View directory record Official record
Conditions
Cancer Cachexia
Interventions
RC-1291 HCl
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Greenbrae, California • Boston, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2013 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

Fenretinide in Treating Patients With Solid Tumors

NCT00003250
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fenretinide
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
15 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 22, 2026, 4:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

NCT06470750
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Terminated Phase 3 Interventional Results available

Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

NCT00699374
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
sunitinib malate, sorafenib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,075 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
35
States / cities
Fountain Valley, California • La Jolla, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 22, 2026, 4:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

NCT04941274
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
Abemaciclib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Active, not recruiting Not applicable Interventional

Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer

NCT03196518
View directory record Official record
Conditions
Thyroid Cancer
Interventions
PET Imaging, 18F-tetrafluoroborate (18F-TFB)
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer

NCT00080418
View directory record Official record
Conditions
Neoplasm
Interventions
Liposome Entrapped Paclitaxel Easy to Use
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
3
States / cities
Tampa, Florida • New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors

NCT00080990
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvocidib, fluorouracil, oxaliplatin, leucovorin calcium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 22, 2026, 4:06 AM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

NCT00023790
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

NCT00530816
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
26
States / cities
Scottsdale, Arizona • Beverly Hills, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 22, 2026, 4:06 AM EDT
Terminated No phase listed Observational

Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00897806
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Microarray analysis, Laboratory biomarker analysis
Genetic · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 22, 2026, 4:06 AM EDT
Not listed Phase 2 Interventional

An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma

NCT00685204
View directory record Official record
Conditions
Mesothelioma
Interventions
Milataxel
Drug
Lead sponsor
Taxolog Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 22, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

NCT06067438
View directory record Official record
Conditions
Atrial Fibrillation, Esophageal Carcinoma
Interventions
Amiodarone Hydrochloride, Saline
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 4:06 AM EDT